A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

Investing.com-- TheraVectys SA is considering an initial public offering in Hong Kong that could raise a few hundred million dollars, marking a rare potential listing by a non-Chinese biotechnology ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also ...

C4 Therapeutics Inc. (NASDAQ: CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, ...